MedKoo Cat#: 597384 | Name: Plipastatin B 1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Plipastatin B 1 is a lipopeptide.

Chemical Structure

Plipastatin B 1
Plipastatin B 1
CAS#103955-73-3

Theoretical Analysis

MedKoo Cat#: 597384

Name: Plipastatin B 1

CAS#: 103955-73-3

Chemical Formula: C74H114N12O20

Exact Mass: 1490.8272

Molecular Weight: 1491.79

Elemental Analysis: C, 59.58; H, 7.70; N, 11.27; O, 21.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Plipastatin B 1; Plipastatin A 1, 6-D-valine-;
IUPAC/Chemical Name
(R)-5-(((R)-5-amino-1-(((12S,4R,7R,10R,15S,18R,21R,24S)-4-(3-amino-3-oxopropyl)-10-((S)-sec-butyl)-21-(2-carboxyethyl)-7-(4-hydroxybenzyl)-18-((R)-1-hydroxyethyl)-24-isopropyl-2,5,8,11,16,19,22,25-octaoxo-12-oxa-3,6,9,17,20,23-hexaaza-1(2,1)-pyrrolidina-13(1,4)-benzenacyclopentacosaphane-15-yl)amino)-1-oxopentan-2-yl)amino)-4-((S)-3-hydroxyhexadecanamido)-5-oxopentanoic acid
InChi Key
BBRYHXPVDSFBGT-XVGDWIIJSA-N
InChi Code
InChI=1S/C74H114N12O20/c1-7-9-10-11-12-13-14-15-16-17-18-21-49(89)42-59(91)77-52(33-36-60(92)93)66(97)78-51(22-19-38-75)65(96)81-56-41-47-26-30-50(31-27-47)106-74(105)63(44(5)8-2)84-69(100)55(40-46-24-28-48(88)29-25-46)82-67(98)53(32-35-58(76)90)79-71(102)57-23-20-39-86(57)73(104)62(43(3)4)83-68(99)54(34-37-61(94)95)80-72(103)64(45(6)87)85-70(56)101/h24-31,43-45,49,51-57,62-64,87-89H,7-23,32-42,75H2,1-6H3,(H2,76,90)(H,77,91)(H,78,97)(H,79,102)(H,80,103)(H,81,96)(H,82,98)(H,83,99)(H,84,100)(H,85,101)(H,92,93)(H,94,95)/t44-,45+,49-,51+,52+,53+,54+,55+,56-,57-,62-,63+,64+/m0/s1
SMILES Code
O=C(C[C@H](CCCCCCCCCCCCC)O)N[C@@H](C(N[C@H](CCCN)C(N[C@@H]1C(N[C@H]([C@H](O)C)C(N[C@H](CCC(O)=O)C(N[C@H](C(N2[C@H](C(N[C@H](CCC(N)=O)C(N[C@H](Cc3ccc(O)cc3)C(N[C@H]([C@H](CC)C)C(Oc4ccc(C1)cc4)=O)=O)=O)=O)CCC2)=O)C(C)C)=O)=O)=O)=O)=O)CCC(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,491.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Coutte F, Leclère V, Béchet M, Guez JS, Lecouturier D, Chollet-Imbert M, Dhulster P, Jacques P. Effect of pps disruption and constitutive expression of srfA on surfactin productivity, spreading and antagonistic properties of Bacillus subtilis 168 derivatives. J Appl Microbiol. 2010 Aug;109(2):480-91. doi: 10.1111/j.1365-2672.2010.04683.x. Epub 2010 Jan 22. PubMed PMID: 20148996. 2: Roongsawang N, Thaniyavarn J, Thaniyavarn S, Kameyama T, Haruki M, Imanaka T, Morikawa M, Kanaya S. Isolation and characterization of a halotolerant Bacillus subtilis BBK-1 which produces three kinds of lipopeptides: bacillomycin L, plipastatin, and surfactin. Extremophiles. 2002 Dec;6(6):499-506. Epub 2002 Sep 13. PubMed PMID: 12486459. 3: Volpon L, Besson F, Lancelin JM. NMR structure of antibiotics plipastatins A and B from Bacillus subtilis inhibitors of phospholipase A(2). FEBS Lett. 2000 Nov 17;485(1):76-80. PubMed PMID: 11086169. 4: Tsuge K, Ano T, Shoda M. Isolation of a gene essential for biosynthesis of the lipopeptide antibiotics plipastatin B1 and surfactin in Bacillus subtilis YB8. Arch Microbiol. 1996 Apr;165(4):243-51. PubMed PMID: 8639027. 5: Yaseen Y, Gancel F, Drider D, Béchet M, Jacques P. Influence of promoters on the production of fengycin in Bacillus spp. Res Microbiol. 2016 May;167(4):272-281. doi: 10.1016/j.resmic.2016.01.008. Epub 2016 Feb 18. PubMed PMID: 26912322. 6: Nishito Y, Osana Y, Hachiya T, Popendorf K, Toyoda A, Fujiyama A, Itaya M, Sakakibara Y. Whole genome assembly of a natto production strain Bacillus subtilis natto from very short read data. BMC Genomics. 2010 Apr 16;11:243. doi: 10.1186/1471-2164-11-243. PubMed PMID: 20398357; PubMed Central PMCID: PMC2867830. 7: Moyne AL, Cleveland TE, Tuzun S. Molecular characterization and analysis of the operon encoding the antifungal lipopeptide bacillomycin D. FEMS Microbiol Lett. 2004 May 1;234(1):43-9. PubMed PMID: 15109718. 8: Gao L, Han J, Liu H, Qu X, Lu Z, Bie X. Plipastatin and surfactin coproduction by Bacillus subtilis pB2-L and their effects on microorganisms. Antonie Van Leeuwenhoek. 2017 Aug;110(8):1007-1018. doi: 10.1007/s10482-017-0874-y. Epub 2017 May 5. PubMed PMID: 28477175.